A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension.
File(s)
Published version
Author(s)
Type
Journal Article
Abstract
Pulmonary arterial hypertension (PAH) is a chronic and progressive disease which continues to carry an unacceptably high mortality and morbidity. The nitric oxide (NO) pathway has been implicated in the pathophysiology and progression of the disease. Its extremely short half-life and systemic effects have hampered the clinical use of NO in PAH. In an attempt to circumvent these major limitations, we have developed a new NO-nanomedicine formulation. The formulation was based on hydrogel-like polymeric composite NO-releasing nanoparticles (NO-RP). The kinetics of NO release from the NO-RP showed a peak at about 120 min followed by a sustained release for over 8 h. The NO-RP did not affect the viability or inflammation responses of endothelial cells. The NO-RP produced concentration-dependent relaxations of pulmonary arteries in mice with PAH induced by hypoxia. In conclusion, NO-RP drugs could considerably enhance the therapeutic potential of NO therapy for PAH.
Date Issued
2016-03-09
Date Acceptance
2016-02-17
Citation
Journal of Cardiovascular Translational Research, 2016, 9 (2), pp.162-164
ISSN
1937-5395
Publisher
Springer Verlag (Germany)
Start Page
162
End Page
164
Journal / Book Title
Journal of Cardiovascular Translational Research
Volume
9
Issue
2
Copyright Statement
© The Author(s) 2016. This article is published with open access at Springerlink.com
License URL
Sponsor
British Heart Foundation
Qatar Foundation
Identifier
PII: 10.1007/s12265-016-9684-2
Grant Number
PG/12/67/29773
WHCF_P48739
Subjects
Aorta
Endothelial cells
NO-releasing nanoparticles
Nanomedicine
Nanoparticles
Nitric oxide
Pulmonary arterial hypertension
Pulmonary artery
Pulmonary artery vascular smooth muscle cells
Publication Status
Published